ondansetron solution
atlantic biologicals corps - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron hydrochloride 4 mg in 5 ml - 1. prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m . 2 2. prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron oral solution, usp is recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansteron is contraindicated based on reports of profound hypotension and loss of consci
ondansetron hydrochloride tablet, film coated
aidarex pharmaceuticals llc - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets, usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administe
ondansetron hydrochloride tablet, film coated
blenheim pharmacal, inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 8 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m 2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets, usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphi
ondansetron hydrochloride tablet, film coated
medvantx, inc. - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. ondansetron tablets are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.
ondansetron- ondansetron hydrochloride tablet, film coated
kaiser foundation hospitals - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered
ondansetron tablet, orally disintegrating
hhs/program support center/supply service center - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 8 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. ondansetron orally disintegrating tablets are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that
ondansetron tablet orally disintegrating
pd-rx pharmaceuticals, inc. - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 4 mg
ondansetron hydrochloride tablet, film coated
rebel distributors corp - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 4 mg - 1. prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m2 . 2. prevention of nausea and vomiting associated with initial and repeat course of moderately emetogenic cancer chemotherapy. 3. prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron tablets are recommended even where the incidence of postoperative nausea and/or vomiting is low. ondansetron tablets are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondansetron is not discriminated as a benz
ondansetron tablet, orally disintegrating
st marys medical park pharmacy - ondansetron (unii: 4af302esos) (ondansetron - unii:4af302esos) - ondansetron 8 mg - - prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥50 mg/m 2 . - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. - prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. - prevention of postoperative nausea and/or vomiting. as with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. in patients where nausea and/or vomiting must be avoided postoperatively, ondansetron orally disintegrating tablets, usp are recommended even where the incidence of postoperative nausea and/or vomiting is low. the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consci
ondansetron hydrochloride tablet, film coated
proficient rx lp - ondansetron hydrochloride (unii: nmh84ozk2b) (ondansetron - unii:4af302esos) - ondansetron 8 mg - the concomitant use of apomorphine with ondansetron is contraindicated based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron. ondansetron tablets are contraindicated for patients known to have hypersensitivity to the drug. animal studies have shown that ondansetron is not discriminated as a benzodiazepine nor does it substitute for benzodiazepines in direct addiction studies.